European Journal of Molecular & Clinical Medicine

Abstract

Background: Androgenetic alopecia (AGA) is the most common form of hair loss experienced in genetically predisposed individuals. The present study evaluated efficacy and safety of 5% minoxidil and 1 mg finasteride in Androgenetic Alopecia male patients.
Materials & Methods: 74 male Androgenetic Alopecia male patients were divided into 2 groups. Group I patients received minoxidil 5% topical solution 1 ml twice a day and group II received oral finasteride 1 mg tablet once a day. Standardized colour global photographs of the affected area were taken and baseline and post‑treatment photographs were compared.
Results: Age group 20-40 years had 14, 40-60 years had 25 and >60 years had 35 patients. The difference was significant (P< 0.05). The mean scalp hair count in group I before treatment was 94.2 per square centimetre and in group II was 96.4 per square centimetre. The mean scalp hair count in group I after treatment was 116.4 per square centimetre and in group II was 106.2 per square centimetre. The difference was significant (P< 0.05). Score -1 was seen in 3 in group II, 0 in 17 in group I and 10 in group II, 1 in 8 in group I and 6 in group II, 2 in 6 in group I and 8 in group II and 3 in 6 in group I and 10 in group II. The difference was significant (P< 0.05).
Conclusion: Oral 1 mg finasteride was found to be more effective than topical 5% minoxidil in management of Androgenetic Alopecia.